Incyte Corporation
Clinical trials sponsored by Incyte Corporation, explained in plain language.
-
New hope for rare blood cancer: targeted drug enters final testing
Disease control Not yet recruitingThis study tests a new drug, INCA033989, against the best current treatments for people with a rare blood cancer called essential thrombocythemia who have a specific gene mutation (CALR). About 426 adults who have already tried at least one prior therapy will be randomly assigned…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
New drug INCB123667 tested in kidney patients for safety
Knowledge-focused Not yet recruitingThis early-stage study looks at how safe a new drug called INCB123667 is for people with severe kidney disease or kidney failure. Researchers will measure how the drug moves through the body and check for side effects. The study involves 16 adults aged 18 to 85.
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:07 UTC
-
New drug safety check for liver patients
Knowledge-focused Not yet recruitingThis early-stage study looks at how a new drug, INCB123667, behaves in the bodies of 16 adults with moderate or severe liver disease. Researchers will measure drug levels and watch for side effects. The goal is to gather safety information, not to treat the liver condition.
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Knowledge-focused
Last updated Jun 11, 2026 12:12 UTC